Company revenues are primarily generated through the sale of disposable kits used during each treatment procedure. Long-term, revenues may also come from sales of TRANBERG® | Mobile Laser Units and technical service. The price for the disposable kit is coupled to the health economic value of the imILT®/FLA treatment which is considered to be significant. The disposable kits are therefore positioned as premium products, offering substantial benefit to healthcare providers in the treatment of solid cancer tumors. Our targeted customers are hospitals involved in multidisciplinary cancer treatment.
Today CLS focuses a large part of its efforts on clinical evaluation of imILT® and the TRANBERG® | Cancer Immunotherapy System. Given our regulatory approval, the mechanism of action and the technology used in our device, imILT® can be performed in all types of solid malignant tumors, with the exception of those located in hollow organs. Investigating the clinical outcome of imILT® is the obvious goal for our clinical studies which is carried out in cooperation with European KOLs. imILT® treatment in the clinical studies include cancer in: breast, liver, lung, pancreas, prostate and skin.
An evaluation of CLS’ products, primarily the disposable kits, for treatment with Focal Laser Ablation (FLA) is initiated in the beginning of 2017 in cooperation with University of Texas Medical Branch.
Initial market entry will take place in Europe, based on successful outcome of our clinical study program. Targeted user groups include medical specialists in surgical oncology and oncologic interventional radiology. Letters of intent are signed with four hospitals with the objectiv to make these reference centers in Europe for imILT®. They will play a key role in market expansion and to facilitate adoption of imILT® into routine clinical use. In order to facilitate early adoption TRANBERG® | Mobile Laser Units will be offered through financially favorable deals including disposable kits.